Premium
Interleukin‐6 concentration changes in plasma and saliva in bisphosphonate‐related osteonecrosis of the jaws
Author(s) -
Bagan J,
Sáez GT,
Tormos MC,
Hens E,
Terol MJ,
Bagan L,
DiazFernández JM,
Lluch A,
Camps C
Publication year - 2014
Publication title -
oral diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.953
H-Index - 87
eISSN - 1601-0825
pISSN - 1354-523X
DOI - 10.1111/odi.12150
Subject(s) - saliva , medicine , bisphosphonate , gastroenterology , etiology , dentistry , osteoporosis
Aim To determine the plasma and saliva levels of IL ‐6 in patients with bisphosphonate‐related osteonecrosis of the jaws ( BRONJ ) and to investigate whether there is a correlation between more advanced stages of BRONJ and levels of IL ‐6. Material and Methods We studied three groups: group 1 consisted of 30 patients with BRONJ due to intravenous bisphosphonates (iv BP ), group 2 consisted of 25 patients treated with iv BP but without BRONJ , and group 3 consisted of 15 healthy controls. In each case, we assayed plasma and saliva IL ‐6 samples using an ELISA test. Results Significantly, higher IL ‐6 values were found in both saliva and plasma in group 1 vs groups 2 and 3 ( P < 0.01). Group 1 showed no differences in plasma or saliva IL ‐6 according to patient gender ( P > 0.05), type of tumor, BRONJ location, etiology of BRONJ , or disease stage ( P > 0.05). We found higher plasma and saliva IL ‐6 values in the more advances stages of BRONJ , although the differences were not statistically significant. Conclusions Plasma and saliva IL ‐6 values were higher in our patients with BRONJ than in controls and therefore might be a useful tool for monitoring the severity of BRONJ.